Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the ...

Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The retina is the innermost layer of the eye, which is involved in receiving visual input and sending the light signal to the brain via the optic nerve. The blood supply to the retina is provided via ...

I read the article by Shah and Shah 1 with great interest. I congratulate the authors for evaluating the effects of early single intravitreal injection of bevacizumab followed by panretinal and ...

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder that can result in severe visual acuity loss. The randomized control study, CRUISE, helped establish anti-VEGFs as the ...

Having high cholesterol can be dangerous as it often goes unnoticed due to the condition being asymptomatic. Some common symptoms of high cholesterol, however, are known to change how the eyes or the ...

"Central Retinal Vein Occlusion Pipeline Insight"The Central Retinal Vein Occlusion (CRVO) treatment landscape is advancing, with several companies developing novel therapies to improve outcomes. CRVO ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical ...

Leuven, April 23, 2015 - ThromboGenics NV (Euronext Brussels:THR), an integrated biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of ...